MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.42
-0.05
-0.77%
After Hours: 6.42 0 0.00% 16:49 09/18 EDT
OPEN
6.44
PREV CLOSE
6.47
HIGH
6.54
LOW
6.33
VOLUME
1.20M
TURNOVER
--
52 WEEK HIGH
9.49
52 WEEK LOW
3.320
MARKET CAP
608.33M
P/E (TTM)
-3.2965
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TGTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TGTX News

  • Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
  • Simply Wall St..1d ago
  • TG's ublituximab shows favorable long-term safety profile in extension study
  • seekingalpha.6d ago
  • The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study
  • Benzinga.6d ago
  • TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
  • GlobeNewswire.6d ago

More

Industry

Biotechnology & Medical Research
-0.68%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About TGTX

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
More

Webull offers TG Therapeutics Inc (TGTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.